Laryngeal Cancer - A Pipeline Analysis Report

Overview of the drug development pipeline for laryngeal cancer

Laryngeal cancer, also known as larynx cancer, is a type of head and neck cancer where tumor cells are formed in the tissues of the larynx. The larynx is a part of the throat, and it is situated between the tongue and trachea. The causes of laryngeal cancer are smoking, eating tobacco, and drinking excessive alcohol. It can also be caused due to the human papillomavirus. Exposure to some chemical substance such as formaldehyde, nickel, isopropyl alcohol, and regular exposure to high levels of wood dust, coal dust, paint fumes, coal as a source of fuel can result in laryngeal cancer. According to the Centers for Disease Control and Prevention (CDC), around 10,000 men and approximately 2,500 women are diagnosed with laryngeal cancer in the US every year. Combination therapy is emerging as the most efficient approach for the treatment of laryngeal cancer.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for head and neck cancer. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Drug development for laryngeal cancer market report: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of laryngeal cancer. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• AstraZeneca
• Benitec Biopharma
• Cellectar Biosciences

Therapeutic assessment of the drug development pipeline for laryngeal cancer by route of administration

• Oral
• Unknown

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for laryngeal cancer by therapy

• Combination therapy
• Unknown

According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for laryngeal cancer are being developed as combination drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the gene therapy molecules in the various development stages for laryngeal cancer?
• What are the companies that are currently involved in the development of drug molecules for laryngeal cancer?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.